Signadori Bio
Signadori Bio
Agent40Agent Readiness: 40/100. Below median. Measured by StartupHub.ai. Median 41.Developing a next-generation, off-the-shelf, in vivo engineered monocyte immunotherapy platform for solid tumors.
About
Signadori Bio SAS is a preclinical-stage biopharmaceutical company focused on developing an innovative immunotherapy platform. Their approach utilizes in vivo engineered monocytes, designed to be an off-the-shelf solution for treating solid tumors. The company aims to advance novel therapeutic strategies in oncology.
Key facts
At-a-glance profile data
- Website
- signadoribio.com
- Headquarters
- Paris, France
- Founded
- 2025
- Total funding
- $12M (Seed Extension)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 6 May 2026 | Seed Extension | $11M | - |
| 7 Apr 2025 | Seed | $1M | - |
Tech stack
Detected on signadoribio.com, last scanned 11 Jul 2026. Run your own scan
- CMS / Builders
- Lovable
- CDN
- Cloudflare
- Email provider
- Microsoft 365
Add first review
Frequently asked
How much funding has Signadori Bio raised?
Signadori Bio has raised a total of $12M in funding. The most recent round on record is Seed Extension.
What is Signadori Bio's current status?
Signadori Bio's current operating status is: Inactive.